Skip to main content

Advertisement

Table 3 HLA-B*5701 prevalence studies conducted in different regions across the world

From: HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia

Country, publication year Number of subjects Prevalence HLA-B*5701 screening recommendation Reference
Australia, 2006 260 7.7% Yes [15]
Taiwan, 2007 320 0.3% No [18]
19 countries, 2008 1956 5.6% Yes [14]
Chile, 2010 492 2.2% Yes [23]
México, 2011 300 2% Yes [24]
Brazil, 2011 96 3.1% Yes [26]
Brazil, 2014 517 5.6% Yes [12]
Costa Rica, 2014 200 5% Yes [25]
Argentina, 2015 1646 4.9% Yes [27]
Iran, 2016 198 3% HLA-B*5701 may reduce risk, but there are cost issues [22]
USA, 2017 385 3.4% Yes [21]